ENABLING PRECISION MEDICINE
Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. Our initial M3 emitter product line enables unprecedented gains in sensitivity, throughput, and robustness for liquid chromatography-mass spectrometry (LC-MS). The multinozzle emitter array (MEA) technology, invented at the Lawrence Berkeley National Laboratory, won the 2012 R&D 100 award.
We are applying our technology to develop multi-omics diagnostic assays for diabetes, Alzheimer’s, and other diseases. We are also developing a microfluidic device to sort, count, and remove cells based on size from blood (the Senescence Chip). The impact of our publications led to a ranking of #71 among the top 100 corporations in the US that dominated research in the natural sciences in 2018.